Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Vyne Therapeutics Inc (VYNE)

Vyne Therapeutics Inc (VYNE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 35,529
  • Shares Outstanding, K 14,099
  • Annual Sales, $ 420 K
  • Annual Income, $ -28,450 K
  • 60-Month Beta 1.23
  • Price/Sales 87.45
  • Price/Cash Flow N/A
  • Price/Book 0.39
Trade VYNE with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.24
  • Number of Estimates 1
  • High Estimate -0.24
  • Low Estimate -0.24
  • Prior Year -1.74
  • Growth Rate Est. (year over year) +86.21%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.24 +12.05%
on 04/22/24
3.14 -20.06%
on 04/02/24
-0.57 (-18.51%)
since 04/01/24
3-Month
1.77 +41.81%
on 02/02/24
3.17 -20.82%
on 04/01/24
+0.69 (+37.91%)
since 02/01/24
52-Week
1.67 +50.30%
on 01/31/24
8.73 -71.25%
on 05/09/23
-3.53 (-58.44%)
since 05/01/23

Most Recent Stories

More News
VYNE Gains on Preclinical Data for IPF Candidate

VYNE gains on positive preclinical data evaluating VYN201 for treating idiopathic pulmonary fibrosis.

CRSP : 52.92 (-0.13%)
KALA : 7.07 (+3.67%)
ALLO : 2.81 (+1.81%)
VYNE : 2.57 (+1.98%)
VYNE Therapeutics (NASDAQ: VYNE) Shares Positive Preclinical Data for VYN201 as a Potential Treatment for Idiopathic Pulmonary Fibrosis

VYNE Therapeutics, Inc. (NASDAQ: VYNE) is engaged as a clinical-stage biopharma company, which is focused on the research and development

VYNE : 2.57 (+1.98%)
Pre-Market Brief: Stocks Mostly Lower As Hawkish Fed Remarks Weigh On Sentiment, Powell Speech In Focus

March S&P 500 futures (ESH23) are trending down -0.08% this morning after three major U.S. benchmark indices ended the regular session mixed following hawkish remarks from two U.S. Federal Reserve officials,...

ESH23 : 3,957.05s (-0.09%)
AAPL : 171.12 (+0.46%)
GOOGL : 164.22 (+0.88%)
MSFT : 394.81 (+1.41%)
NVDA : 820.90 (-4.99%)
OSH : 39.00 (+0.08%)
VYNE : 2.57 (+1.98%)
FRO : 23.33 (-0.68%)
BLI : 1.2000 (-5.88%)
WWW : 10.39 (-3.26%)
VYNE Therapeutics Inc. (VYNE) Reports Q3 Loss, Tops Revenue Estimates

VYNE Therapeutics Inc. (VYNE) delivered earnings and revenue surprises of 0% and 67%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

VYNE : 2.57 (+1.98%)
MDWD : 19.15 (+2.90%)
VYNE Therapeutics Announces Results from its Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis

BRIDGEWATER, N.J., Aug. 10, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company...

VYNE : 2.57 (+1.98%)
Catalyst Pharmaceutical (CPRX) Q2 Earnings and Revenues Top Estimates

Catalyst (CPRX) delivered earnings and revenue surprises of 17.65% and 7.75%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

CPRX : 15.16 (+0.73%)
VYNE : 2.57 (+1.98%)
VYNE Therapeutics to Present at the B&T Cell-Mediated Autoimmune Disease Drug Development Conference

BRIDGEWATER, N.J., July 19, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company...

VYNE : 2.57 (+1.98%)
VYNE Therapeutics Completes Enrollment in Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis

Top-line Efficacy Results Expected in Approximately 6 to 8 Weeks...

VYNE : 2.57 (+1.98%)
VYNE Therapeutics to Present at HC Wainwright & Co. Global Investment Conference

BRIDGEWATER, N.J., May 18, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company...

VYNE : 2.57 (+1.98%)
VYNE Therapeutics Inc. (VYNE) Reports Q1 Loss, Misses Revenue Estimates

VYNE Therapeutics Inc. (VYNE) delivered earnings and revenue surprises of 6.67% and 67.64%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

VYNE : 2.57 (+1.98%)
HQY : 80.16 (+1.58%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

VYNE Therapeutics Inc. focuses on developing and commercializing therapeutics for dermatology. The company's product pipeline consist FMX103 and FCD105 which are in clinical stage. VYNE Therapeutics Inc., formerly known as Menlo Therapeutics Inc., is based in Bridgewater, New Jersey.

See More

Key Turning Points

3rd Resistance Point 2.83
2nd Resistance Point 2.72
1st Resistance Point 2.62
Last Price 2.57
1st Support Level 2.41
2nd Support Level 2.30
3rd Support Level 2.20

See More

52-Week High 8.73
Fibonacci 61.8% 6.03
Fibonacci 50% 5.20
Fibonacci 38.2% 4.37
Last Price 2.57
52-Week Low 1.67

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar